-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Untangling Amyloidosis 2023: Diagnosis, Prognosis, Selection of Individualized Therapy, and Management of Difficult Clinical Complications

Sponsor: Karmanos Cancer Institute, Prothena Biosciences Limited, Amyloidosis Foundation, Amyloidosis Support Groups Inc., Amyloidosis Speakers Bureau, Alnylam Pharmaceuticals, Inc., and Janssen Biotech, Inc.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Diseases, Therapies, Biological Processes
Friday, December 8, 2023: 11:00 AM-2:00 PM
Ballroom 20AB (San Diego Convention Center)
Jeffrey A. Zonder, MD, Karmanos Cancer Institute
Zonder: Takeda, Telios: Other: Consultancy which has ended within the past 24 months; Bristol-Myers Squibb/Celgene: Research Funding; Janssen, Prothena, Regeneron: Consultancy.
Eli Muchtar, MD, Mayo Clinic , Giada Bianchi, MD, Brigham and Women's Hospital , Laura Obici, MD, Fondazione IRCCS Policlinico San Matteo and Rafat Abonour, MD, Indiana University School of Medicine
Muchtar: Protego: Consultancy. Bianchi: Prothena: Consultancy. Obici: Pfizer, Alnylam, SOBI: Consultancy, Honoraria; Astra Zeneca, BridgeBio, Novo Nordisk: Consultancy. Abonour: BMS, Janssen, Takeda: Consultancy; BMS, Janssen, Pfizer: Honoraria.
On Demand program will be available here December 29, 2023.

The Karmanos Cancer Institute, in collaboration with the Amyloidosis Support Groups, Inc., is developing a CME symposium to be conducted on Friday, December 8th, 2023, preceding the annual American Society of Hematology (ASH) meeting. It will consist of evidence-based presentations focused on the diagnosis, pathophysiology, prognosis, and treatment of systemic amyloidosis. The complexities of making a timely, accurate diagnosis of amyloidosis will be discussed, with emphasis placed on distinguishing AL amyloidosis from the other most common type of amyloidosis, ATTR. Selection of appropriate initial anti-plasma cell therapy of AL amyloidosis will be highlighted. Investigational light chain and fibril-directed agents will be discussed, as will novel potential therapeutic strategies mirroring approved ATTR therapies. Finally, we will review the pathophysiology of bleeding and clotting complications in AL amyloidosis, providing attendees practical clinical management guidance. We intend to live-stream the presentations to expand the audience beyond those attending in-person. The program is intended to be interactive and the live audience will be asked to provide opinions and answers to questions intermittently throughout the program via an audience response system (ARS). A panel discussion after the speakers' presentations will provide an opportunity to address questions from the live audience.